The ACR and EULAR affirm that JAK inhibitors could be a viable option for RA patients who are refractory to methotrexate monotherapy and viewed on equal footing with TNF inhibitors and non-TNF biologics such as abatacept, tocilizumab and rituximab (13, 240). The gene discussed is TNF; the disease is rheumatoid arthritis.